Merck KGaA (XTER:MRK)
€ 154.5 -1 (-0.64%) Market Cap: 67.17 Bil Enterprise Value: 75.03 Bil PE Ratio: 23.81 PB Ratio: 2.52 GF Score: 90/100

Merck KGaA R&D Update Call Transcript

Nov 21, 2022 / 01:00PM GMT
Release Date Price: €174.95 (-0.71%)
Operator

Dear ladies and gentlemen, welcome to the Merck R&D update call. (Operator Instructions) May I now hand you over to Constantin Fest, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir.

Constantin Fest
MERCK Kommanditgesellschaft auf Aktien - Head of IR

Thank you very much, Heidi. Dear ladies and gentlemen, a very warm welcome to this Merck 2022 Healthcare R&D Update Call.

My name is Constantin Fest, I'm Head of Investor Relations at Merck. And I'm delighted to be joined today by the following presenters. We have Danny Bar-Zohar, Global Head of Research and Development and Chief Medical Officer; Klaus Urbahns, Global Head of Discovery and Development Technologies; Victoria Zazulina, Global Head of Development Unit Oncology; and Jan Klatt, Global Head of Development Unit Neurology & Immunology. Please note, also joining for the Q&A part of this call is Andrew Paterson, Chief Marketing Officer.

In the next 50 to 60 minutes, we'd like to run you through the key slides of this presentation,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot